Drug Trial Radar · NCT07905924
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Mar 30, 2032
Study completion Mar 30, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of RO7836748 as monotherapy and in combination with other anti-cancer therapies, including cetuximab, pembrolizumab, or modified (m)FOLFIRINOX in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12V-positive solid tumors such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC), and other solid tumors.
Conditions
- Solid Tumors
Interventions
RO7836748Drug
Participants will receive RO7836748 as per the schedule described in the protocol.
PembrolizumabDrug
Participants will receive pembrolizumab as per the schedule described in the protocol.
mFOLFIRINOXDrug
Participants will receive mFOLFIRINOX as per the schedule described in the protocol.
CetuximabDrug
Participants will receive cetuximab as per the schedule described in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1A and 1B: Incidence and Severity of Adverse Events (AEs)Time frame: From first dose up to approximately 5 years
- Part 2: Incidence and Severity of AEsTime frame: From first dose up to approximately 5 years
- Parts 3A, 3B and 3C: Incidence and Severity of AEsTime frame: From first dose up to approximately 5 years
- Parts 1A and 1B: Incidence of Dose-limiting Toxicities (DLTs)Time frame: From Cycle 1 Day 1 (C1D1) until C1D21 (Cycle 1 = 21 days)
- Part 3A: Incidence of DLTsTime frame: From C1D1 until C1D21 (Cycle 1 = 21 days)
- Parts 3B and 3C: Incidence of DLTsTime frame: From C1D1 until C1D28 (Cycle 1 = 28 days)
- Parts 1A and 1B: Recommended Dose for Expansion (RDE) of RO7836748 MonotherapyTime frame: Up to approximately 5 years
- Parts 3A, 3B, 3C: RDE of RO7836748 in Combination With Other Anti-Cancer TherapiesTime frame: Up to approximately 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.